基于生物标志物的Savolitinib治疗晚期乳头状肾细胞癌的II期试验
这项单臂、多中心II期研究评估了Savolitinib在晚期乳头状肾细胞癌(PRCC)患者中的安全性和疗效,并按MET状态分析。109例患者接受Savolitinib 600 mg每日一次口服,MET驱动型PRCC与缓解强烈相关,MET驱动型与MET非驱动型的中位无进展生存期分别为6.2个月和1.4个月(HR 0.33)。作者认为这些发现支持在MET驱动型PRCC中进一步研究Savolitinib。
要点
- MET驱动型PRCC患者中8例确认部分缓解(18%),MET非驱动型无一例缓解(P = .002)。
- MET驱动型与MET非驱动型中位PFS分别为6.2个月与1.4个月(HR 0.33,95%CI 0.20-0.52,log-rank P < .001)。
- Savolitinib最常见不良事件为恶心、乏力、呕吐和外周水肿。
核心结论
- 这些数据表明Savolitinib在MET驱动型PRCC患者亚组中具有活性和耐受性。
- MET状态的分子特征比基于病理学的分类更能预测Savolitinib的缓解。
- 这些发现支持在MET驱动型PRCC中研究Savolitinib。
研究设计与样本
- 单臂、多中心、II期研究,评估Savolitinib在PRCC患者中按MET状态分析的安全性和疗效。
- 入组组织学确诊的局部晚期或转移性PRCC患者,接受Savolitinib 600 mg每日一次口服。
- MET驱动型PRCC定义为以下任一:7号染色体拷贝数增加、MET或HGF基因局灶性扩增、或MET激酶结构域突变。
- 共109例患者接受治疗,MET驱动型44例(40%),MET非驱动型46例(42%),MET状态未知19例(17%)。
- 在所有患者中评估安全性、毒性及患者报告的健康相关生活质量结局。
主要发现
- MET驱动型PRCC与缓解强烈相关:MET驱动型疾病有8例确认部分缓解(18%),MET非驱动型疾病无一例缓解(P = .002)。
- MET驱动型与MET非驱动型PRCC的中位无进展生存期分别为6.2个月(95%CI 4.1-7.0个月)与1.4个月(95%CI 1.4-2.7个月)(HR 0.33;95%CI 0.20-0.52;log-rank P < .001)。
- 与Savolitinib相关的最常见不良事件为恶心、乏力、呕吐和外周水肿。
关键数值与推荐
- MET驱动型PRCC定义:7号染色体拷贝数增加、MET或HGF基因局灶性扩增、或MET激酶结构域突变。
- Savolitinib给药方案:600 mg每日一次口服。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Patients with advanced papillary renal cell carcinoma (PRCC) have limited therapeutic options. PRCC may involve activation of the MET pathway, for example, through gene amplification or mutations. Savolitinib (AZD6094, HMPL-504, volitinib) is a highly selective MET tyrosine kinase inhibitor. We report results of a single-arm, multicenter, phase II study evaluating the safety and efficacy of savolitinib in patients with PRCC according to MET status. Patients and Methods Patients with histologically confirmed locally advanced or metastatic PRCC were enrolled and received savolitinib 600 mg orally once daily. MET-driven PRCC was defined as any of the following: chromosome 7 copy gain, focal MET or HGF gene amplification, or MET kinase domain mutations. Efficacy was assessed according to MET status. Safety, toxicity, and patient-reported health-related quality-of-life outcomes were assessed in all patients. Results Of 109 patients treated, PRCC was MET driven in 44 (40%) and MET independent in 46 (42%); MET status was unknown in 19 (17%). MET-driven PRCC was strongly associated with response; there were eight confirmed partial responders with MET-driven disease (18%), but none with MET-independent disease ( P = .002). Median progression-free survival for patients with MET-driven and MET-independent PRCC was 6.2 months (95% CI, 4.1 to 7.0 months) and 1.4 months (95% CI, 1.4 to 2.7 months), respectively (hazard ratio, 0.33; 95% CI, 0.20 to 0.52; log-rank P < .001). The most frequent adverse events associated with savolitinib were nausea, fatigue, vomiting, and peripheral edema. Conclusion These data show activity and tolerability of savolitinib in the subgroup of patients with MET-driven PRCC. Furthermore, molecular characterization of MET status was more predictive of response to savolitinib than a classification based on pathology. These findings justify investigating savolitinib in MET-driven PRCC.
引用
- Choueiri TK, Plimack E, Arkenau HT, et al. Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. J Clin Oncol. 2017. PMID: 28644771. doi:10.1200/JCO.2017.72.2967
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。